Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “ACTH”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 1,045 records · Page 58Linked to original sources

Mutational analysis of evolutionarily conserved ACTH residues.

alpha-Melanocyte stimulating hormone (MSH) and adrenocorticotropin (ACTH)1-24, the minimal ACTH sequence required for full activity, differ only by the 10 C-terminal amino acids of ACTH1-24. Interestingly, these ten C-terminal residues have been highly conserved throughout vertebrate evolution. To understand the functional constraints of these 10 amino acids we analyzed the effects of mutating these residues on steroidogenic activity in vivo and in vitro. Alanine substitutions of some of the first four amino acid residues (the basic core residues KKRR, 15-18) greatly reduces ACTH activity in vitro and in vivo; replacement of mutant alanines at residues 15 and 17 with glutamine residues partially restores ACTH activity. Thus, for ACTH receptor binding and activation, the amino acid residues 15-18 are important for their side chains. Surprisingly, conversion of the five C-terminal residues (20-24) to alanines increases ACTH activity in vivo over that of native ACTH. With respect to receptor binding and activity, the last five amino acid residues are important only for the peptide length they contribute; however, with respect to serum stability, their side chains are significant.

Adrenal Glands↗

ACTH cells of pituitary pars distalis of viscacha (Lagostomus maximus maximus): immunohistochemical study in relation to season, sex, and growth.

Corticotrope or ACTH cells were immunohistochemically identified in the pituitary pars distalis (PD) of viscacha by using the polyclonal antiserum against ACTH (1-24). The localization, distribution, shape, percentage immunopositive area, and major cellular and nuclear diameters of these cells were analyzed by image analysis in adult male viscachas captured in their natural habitat during the year and after the chronic administration of melatonin. The same parameters were analyzed in immature male and adult female viscachas. ACTH cells in adult males were mainly localized in the dorsal and cephalic regions of PD. They were isolated, forming small groups and in contact with follicular structures and blood vessels. They were pleomorphic, with some of them being polygonal, oval, round, and others, stellate with cytoplasmic extensions. The percentage immunopositive area and the major cellular diameter showed seasonal variations with lower values during June and July (early winter). A decrease in the percentage immunopositive area was observed after the administration of melatonin in adult male animals. ACTH cells of immature animals differed from the adults' cells in their distribution, shape, pattern of immunolabeling, and percentage immunopositive area. These parameters in adult females did not vary in relation to adult males at the same time of the year although. However, the cells in females were smaller in size during April-May. In pregnant viscachas (June-July), these parameters did not show significant differences with the results of non-pregnant females (April-May). This suggests that the environmental stressors do not exert the same influence on the hypothalamo-pituitary-adrenal axis in adult male and female viscachas, probably due to the physiological changes caused by pregnancy. Our results in adult male viscacha demonstrate that the morphology of the ACTH cells varies according to the different seasonal conditions, thus participating in the adaptation process of this rodent to the environment. The elevated levels of melatonin during winter months might inhibit the synthesis of ACTH, probably when affecting some secretagogue of this pituitary hormone. Moreover, the morphological variations observed between adult and immature male viscachas and between both sexes suggest that the steroid gonadal hormones might act on the development and activity of ACTH cells.

Adrenocorticotropic Hormone↗

Selectivity of [Phe-I7], [Ala6], and [D-Ala4,Gln5,Tyr6] substituted ACTH(4-10) analogues for the melanocortin receptors.

We tested [Ala6]ACTH(4-10) and [Phe-I7]ACTH(4-10)(putative MC receptor antagonists), [D-Ala4,Gln5,Tyr6]ACTH(4-10)(BIM 22015), and ACTH (4-10) with radioligand binding using transiently expressed human MC1, MC3, MC4, and MC3 receptors. [Phe-I7]ACTH(4-10) had higher affinity for the MC3, MC4, and MC3 receptors but lower for the MC1 compared to ACTH(4-10). [Ala6]ACTH(4-10) did not bind the MC1 receptor but had highest affinity for the MC4 receptor. The data indicate that the His6 has a specially important role in binding to the MC1 receptor. The BIM 22015 did not bind to these MC receptor subtypes, which indicates that the neurotrophic and myotrophic properties that are attributed to this peptide are mediated by some other receptor.

Adrenocorticotropic Hormone↗

Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion in healthy male subjects.

In this single-blind study the effects of acute oral administration of the selective noradrenaline reuptake inhibitor reboxetine on the cortisol (COR), ACTH, growth hormone (GH) and prolactin (PRL) secretion were examined in 12 healthy male volunteers. In a randomized order, the subjects received placebo or reboxetine (4 mg) at 0800 h on two different days. After insertion of an intravenous catheter, blood samples were drawn 1 hour prior to the administration of placebo or reboxetine, at time of administration, and during the time of 5 hours thereafter at periods of 30 minutes. Serum concentrations of COR, GH, and PRL as well as plasma levels of ACTH were determined in each blood sample by means of double antibody RIA, fluoroimmunoassay and chemiluminescence immunometric assay methods. The area under the curve (AUC) value was used as parameter for the COR, ACTH, GH, and PRL response. Using t-tests for paired samples, statistical analysis revealed significant stimulatory effects of reboxetine on COR, ACTH, GH, and PRL secretion, compared to placebo (mean AUC values+/-S.E.M. (a) reboxetine: COR 127893.20+/-8125.75 nmol/l x min; ACTH 2385.68+/-387.19 pmol/l x min; GH 56026.59+/-15594.87 pmol/l x min; PRL 113961.60+/-10280.44 pmol/l x min; (b) placebo: COR 83672.19+/-5225.20 nmol/l x min; ACTH 1449.83+/-190.67 pmol/l x min; GH 9308.16+/-3402.75 pmol/l x min; PRL 64663.28+/-7283.62 pmol/l x min). Mean arterial blood pressure and heart rate were significantly increased by reboxetine, too. Our results suggest that besides COR, ACTH and GH secretion, the release of PRL is also under the control of the noradrenergic systems in man.

Adrenergic Uptake Inhibitors↗

Effects of anterolateral and posterolateral cuts around the medial hypothalamus on the immunoreactive ACTH and beta-endorphin levels in selected brain regions of the rat.

To evaluate the relative weight of the ACTH-ergic and beta-endorphin-ergic pathway(s) leaving the medial hypothalamus (MH) in anterior or posterior directions immunoreactive ACTH and beta-endorphin (ir-ACTH and ir-betaE) were quantified in selected brain regions of the rat 7-8 days after placing anterolateral (ALC) or posterolateral (PLC) cut around the MH. Retrograde accumulation of both peptides was observed in the MH after ALC, but not after PLC. ALC resulted in dramatic decrease in ir-ACTH/ir-betaE concentrations in all extra-MH brain regions tested (extra-MH hypothalamus, septum, thalamus, hippocampus, amygdala, and medulla oblongata). In contrast, ir-ACTH and ir-betaE levels decreased only in the thalamus and in the medulla oblongata after PLC. The present data indicate (a) ACTH- and betaE-like substances synthesized in the arcuate region of the hypothalamus are axonally transported to extrahypothalamic brain regions by neuronal pathways leaving the MH primarily anterolateral, anterodorsal, or anteromedial direction (even the fibers of certain posteromedial or posterolateral projections leave the MH some anterior directions); (b) the posterior ACTH-/betaE-ergic projections seem to be of minor importance except for the thalamus and the medulla oblongata where it contributes to about one-third of the peptide content. Our biochemical study provide quantitative complementary data to the detailed immunohistochemical picture of the ACTH/betaE-ergic projections in the rat brain described by Khachaturian et al.

Adrenocorticotropic Hormone↗

ACTH initiation of mammary secretion in pregnant goats is influenced by the stage of gestation and pre partum milking.

Pregnant goats were treated with ACTH by intramuscular injection (1 mg/d for 2 d) at various stages of pregnancy to investigate its effect on initiation of mammary secretion. ACTH stimulated lactose secretion and increased udder volume at or after 84 d of gestation, when compared with untreated controls. Treatment with ACTH between d 109 and 127 of gestation increased circulating plasma glucose concentration, mammary blood flow and mammary uptake of glucose which returned to pre injection levels 6 d after treatment. Arterial concentrations of progesterone were not affected by ACTH but mammary progesterone uptake increased 2-fold. Pre partum milking alone stimulated mammary secretion in eight of 13 goats. Subsequent treatment with ACTH resulted in no further change in the composition of the secretion but increase in yield was maintained. ACTH stimulated mammary secretion in those goats which did not respond to pre partum milking. It was concluded that ACTH initiated mammary secretion in pregnant goats by mechanisms which interact with the stimulation of milking but which are independent of circulating progesterone levels.

Adrenocorticotropic Hormone↗

ACTH-producing pituitary cancer: experience at the King Faisal Specialist Hospital & Research Centre.

Pituitary gland is an uncommon site of a primary cancer. Of more than 600 cases of pituitary tumors seen at the KFSH&RC between 1975 to 1998 only 3 patients had primary pituitary cancer. We have previously reported a case of pituitary fibrosarcoma arising as a rare complication of external radiotherapy (ERT) for GH-secreting pituitary adenoma (PA) [1]. We report now 2 cases of ACTH-producing primary pituitary carcinoma (ACTH-PPC); their follow-up data provide information on the natural history of this cancer. Patient #1; a 46 year old lady with Cushing's disease (CD) presented with an enlarged right cervical lymph node (LN) 2 years after having undergone a partial hypophysectomy through transsphenoidal surgery (PHYPX/TSS) and ERT for an invasive pituitary tumor. Patient #2; a 26 year old man presented with CD and underwent bilateral adrenalectomy (ADx) and pituitary ERT. Thirty-nine months later he developed Nelson's syndrome and a PHYPX/TSS was performed. Incidentally discovered hepatic metastases in this patient and an excisional biopsy of the LN in patient #1 showed histological features very similar to the pituitary tumor, and they stained strongly positive for ACTH. Perinuclear spherical hyalinized cytoplasmic inclusions were seen in the LN biopsy that corresponded to bundles of type 1 microfilaments (specific for pituitary ACTH-producing cells) seen by electron microscopy. A whole body 18-Fluoro-2-Deoxy-D-Glucose positron emission (FDG-PET) scanning, showed an intense uptake in the neck mass. A trial of octreotide did not change the exceedingly high levels of ACTH in patient #2, further supporting the diagnosis of ACTH-PPC. The clinical course of 102 months prior to his demise showed continued progression of the primary and the metastatic tumor. Patient #1, is alive at 15 months follow-up; hypercortisolemia is controlled using ketoconazole. ACTH-PPC should be entertained in a patient with CD presenting with persistent cervical lymphadenopathy. The clinical course in our patients suggests that the emergence of PC may involve a proliferative continuum from a pre-existing PA to an invasive tumor, culminating in a carcinoma. Adjunctive events such as ERT/ADx may predispose to the evolution of PC in genetically susceptible individuals. Because ERT is an effective treatment for PA its use will continue; it is important to be aware of the possible complication of primary pituitary carcinoma.

Adrenocorticotropic Hormone↗

Glucagon is an ACTH secretagogue as effective as hCRH after intramuscolar administration while it is ineffective when given intravenously in normal subjects.

It is widely accepted that glucagon stimulates GH, ACTH and cortisol release in humans, though the mechanisms underlying these effects are unclear. Aim of the present study was to evaluate the stimulatory effect of intramuscolar (i.m.) and intravenous (i.v.) glucagon (GLU) administration on ACTH, cortisol (F) and GH release in normal adult subjects and to compare its effect on hypothalamo-pituitary adrenal (HPA) axis with that of hCRH. To this goal, in 6 normal young women (26-32 yrs, 50-58 kg) we studied the ACTH and F responses to either i.m. or i.v. GLU (1 mg, approximately 0.017 mg/kg in subjects of 54.1 +/- 1.6 kg) administration as well as to i.v. hCRH (2.0 micrograms/kg) or placebo administration. The GH and glucose variations after GLU administration were also studied. I.v. GLU did not modify the spontaneous decrease of ACTH and cortisol levels observed after placebo. Conversely, i.m. GLU elicited clear-cut ACTH and F responses (peak vs baseline, mean +/- SEM: 53.0 +/- 15.2 vs 19.0 +/- 1.5 pg/ml, p < 0.05 and 222.3 +/- 23.8 vs 158.3 +/- 7.0 micrograms/l, p < 0.05) which were higher than those recorded after hCRH (28.1 +/- 4.6 vs 17.4 +/- 3.1 pg/ml, p < 0.02 and 182.7 +/- 22.8 vs 114.8 +/- 12.3 micrograms/l p < 0.02), though this difference did not attain statistical significance. Also GH rise was recorded after i.m. but not after i.v. GLU administration (11.6 +/- 3.4 vs 3.3 +/- 0.7 micrograms/l, p < 0.05). Thirty min after both i.v. and i.m. GLU administration glucose levels showed a similar increase followed by similar decrease. The intramuscular administration of GLU induced negligible side-effects in some subject (mild and transient nausea) which, on the contrary, were clear in all subjects after its intravenous administration (nausea, vomiting, tachycardia). In conclusion, glucagon "per se" is not an ACTH, cortisol and GH secretagogue. After intramuscular administration glucagon is a stimulus of HPA axis at least as effective as hCRH. The mechanisms underlying the ACTH, cortisol and GH responses to i.m. glucagon unlikely include glucose variations or stress.

Adrenocorticotropic Hormone↗

Corticotropin releasing factor induction of leukocyte-derived immunoreactive ACTH and endorphins.

Human peripheral leukocytes infected by virus or treated with endotoxin will, like unstimulated mouse spleen macrophages, synthesize immunoreactive corticotrophin (ir-ACTH) and endorphins. The ir-ACTH produced appears to be identical with authentic ACTH, while enough of the material has been produced in hypophysectomized mice infected with virus to demonstrate a steroidogenic response. Because the production of ACTH by in vivo pituitary cells and by leukocytes is suppressed by dexamethasone both in vitro and in vitro, suggesting that the production of ACTH and endorphins by leukocytes is indeed controlled, we have investigated the effects of corticotropin releasing-factor (CRF), which is known to regulate the pituitary production of both ACTH and beta-endorphin. We now report that the production of ACTH and endorphins by leukocytes is indeed induced by synthetic CRF and, in turn, suppressed by dexamethasone, suggesting that, as in pituitary cells, the proopiomelanocortin (POMC) gene may be expressed and similarly controlled in leukocytes.

Adrenal Gland Neoplasms↗

ACTH lowers serum lipids in steroid-treated hyperlipemic patients with kidney disease.

The mechanisms behind secondary hyperlipidemia in patients with various chronic inflammatory diseases are not known in detail. We have recently demonstrated that ACTH exerts strong hypolipidemic effects in healthy volunteers. To test the clinical relevance of this finding, we administrated ACTH during three weeks to nine hyperlipidemic steroid-treated patients with kidney disease. Before administration of ACTH 1-24, plasma ACTH concentrations were low. Treatment with ACTH led to 20 to 50% reductions in serum concentrations of triglycerides, cholesterol, LDL cholesterol and Apo B as well as of Lp(a). HDL cholesterol and Apo A1 concentrations increased by 10 to 25%. HL activity in postheparin plasma decreased by about 40% and LPL activity, which was initially low, increased by about 140%. The effects of ACTH were similar in kidney transplant recipients and in patients with inflammatory kidney disease. Our results indicate that hyperlipidemia in steroid treated patients with kidney disease may at least partly be due to iatrogenic ACTH deficiency.

Adrenocorticotropic Hormone↗

Haemodynamic effects of increasing extracellular potassium concentration in ACTH-induced hypertension in sheep.

1. ACTH administration (20 microgram day-1 kg-1) to sheep produces hypertension associated with a raised cardiac output and hypokalaemia. 2. The aim of the present experiments was to detail the haemodynamic changes associated with restoration of the extracellular potassium concentration in sheep with ACTH-induced hypertension. 3. After 7 days of ACTH treatment potassium chloride (10 mmol/h) was infused for 3 days to restore plasma [K+] to the pre-ACTH value. 4. ACTH reduced plasma [K+] from 4.4 +/- 0.1 to 3.2 +/- 0.2 mmol/l but 3 days of potassium chloride infusion returned plasma [K+] to 4.3 +/- 0.2 mmol/l. 5. ACTH increased mean arterial pressure from 67 +/- 2 to 88 +/- 1 mmHg in the first 7 days and it remained elevated during potassium chloride infusion (91 +/- 5 mmHg on day 10). 6. Cardiac output rose with 7 days ACTH treatment from 4.9 +/- 0.2 to 6.0 +/- 0.6 l/min but fell progressively with potassium chloride infusion to 4.9 +/- 0.3 l/min on day 10. 7. These studies suggest that potassium status or extracellular [K+] may play a role in determining the haemodynamic profile associated with steroid-induced hypertension.

Adrenocorticotropic Hormone↗

ACTH stimulates plasma renin and angiotensin II in man.

1. Adrenocorticotropic hormone (ACTH; 10 i.u./day) was infused for 34 h into normal male subjects. Some subjects were additionally treated with propranolol or indomethacin. Others received sham infusions or hydrocortisone infusions instead of ACTH. 2. ACTH, but not sham or hydrocortisone infusions, led to a significant increase in plasma renin activity and angiotensin II concentration with a lag period of 7--10 h and a maximum response after 24 h. ACTH may be a physiological regulator of renin secretion, perhaps through a 'trophic' effect on the juxtaglomerular apparatus. 3. The effect of ACTH on renin is not mediated by a rise in plasma renin substrate, probably not by renal beta-adrenoreceptors, but perhaps by prostaglandins. 4. A dissociation between plasma cortisol and aldosterone during ACTH infusion suggests that ACTH, in this dosage, stimulates aldosterone on the second day through renin and angiotensin II, before its secretion is finally suppressed during more prolonged infusion.

Adrenocorticotropic Hormone↗

Plasma cortisol, PRL, ACTH, AVP and corticotrophin releasing hormone responses to direct current cardioversion and electroconvulsive therapy.

OBJECTIVE: We aimed to evaluate and contrast the hypothalamo-pituitary-adrenal (HPA) response to direct current (DC) cardioversion and electroconvulsive therapy (ECT). SUBJECTS: Six male subjects (mean age 61.2 years, range 46-74) with chronic atrial fibrillation were selected for cardioversion. Six subjects with depression (one male, five female; mean age 43.2 years, range 31-59) were selected for ECT. Those taking glucocorticoid drugs, opiates or beta-adrenoceptor antagonists were excluded. MEASUREMENTS: Patients attended for serial blood sampling on the day of cardioversion or ECT, and for an equivalent time period on a control day at least one week before. Intravenous propofol was given to each subject for anaesthesia on the day of cardioversion or ECT. On both study and control days, blood samples were taken at -30, -15, 0 (just prior to cardioversion or ECT), +5, +10, +15, +30, +60, +90 and +120 minutes for assay of cortisol, PRL, ACTH, AVP and CRH. RESULTS: For cardioversion: plasma cortisol increased from 252.5 +/- 39.8 to a maximum of 721.3 +/- 50 nmol/l at 30 minutes (P < 0.0001 compared with control day). ACTH increased from 12.8 +/- 2.8 to a maximum of 64 +/- 14 pmol/l at 5 minutes (P < 0.0001 compared with control day). AVP increased from 6.6 +/- 3.3 to a maximum of 42.9 +/- 16 pmol/l at 5 minutes post-cardioversion (P < 0.005 compared with control day). PRL increased from 141 +/- 28 mlU/l to a maximum of 873 +/- 219 mlU/l at 10 minutes (P < 0.001 compared with control day). There was no significant difference in CRH responses between cardioversion and control days. There was no significant correlation between total electrical energy delivered and maximum ACTH and AVP responses (R = 0.54 and -0.13, respectively). For ECT: on the day of ECT plasma cortisol increased from 419.5 +/- 25.9 to a maximum of 614.7 +/- 26.9 nmol/l (P < 0.002 compared with control day). ACTH increased from 22.7 +/- 6.2 to a maximum of 77.8 +/- 19.1 pmol/l (P < 0.0003 compared with control day). PRL increased from 771 +/- 317 to a maximum of 3152 +/- 703 mlU/l (P < 0.001 compared with control day, and significantly greater than the peak response to cardioversion, P < 0.03). AVP increased from 13.0 +/- 10.8 to a maximum of 35.1 +/- 5.6 pmol/l (P < 0.02 compared with control day). There was no significant difference in CRH responses between ECT and control days. Peak cortisol and ACTH responses did not differ significantly between ECT and cardioversion. Baseline cortisol levels, however, were significantly higher in the depressed group compared with the cardioversion group, P < 0.02, but not ACTH or AVP. CONCLUSION: Significant hypothalamic-pituitary-adrenal activation and PRL release occur in response to both cardioversion and ECT. AVP may have an important role in mediating the acute ACTH response to electrical stimulation.

Adrenocorticotropic Hormone↗

Adrenal responsiveness to high, low and very low ACTH 1-24 doses in obesity.

OBJECTIVE: To investigate adrenal activity in visceral obesity in which adrenal hyperactivity has been hypothesized. This could reflect hypothalamus-pituitary alterations leading to slight hyperfunction of the adrenal. Primary adrenal hypersensitivity to ACTH drive in obesity has also been suggested. However, it has also been reported that dehydroepiondrosterone (DHEA) levels in obesity are reduced and it has been hypothesized that this could play a role in the increased cardiovascular risk in obese patients. SUBJECTS: We have studied seven obese women with visceral adiposity (OB, age: 33.6+/-3.3 years, BMI: 33.8+/-1.3 kg/m2, WHR: 0.88+/-0.01). The results in OB were compared with those recorded in a group of age-matched normal women (NS, age: 30+/-1.3 years, BMI: 19.9+/-0.4 kg/m2, WHR: 0.76+/-0.02). METHODS: We have studied the cortisol (F), aldosterone (A) and DHEA responses to ACTH 1-24 administered at low (LD, 0.5 microg/m2) or very low (VLD, 0.125 microg/m2) dose followed by a second challenge with supramaximal dose (HD, 250 microg). RESULTS: Basal F, A and DHEA levels in OB were similar to those in NS. The peak F responses to ACTH were dose-related in both groups. At each dose the F peaks in OB (VLD: 495.6+/-43.9 nmol/l, HD: 722.3+/-67.7 nmol/l; LD: 519.2+/-46.0 nmol/l, HD: 729.6+/-44.7 nmol/l) were similar to those in NS (VLD: 556.7+/-45.9 nmol/l, HD: 704.8+/-20.7 nmol/l; LD: 511.8+/-22.8 nmol/l, HD: 726.7+/-26.5 nmol/l). The peak A responses to ACTH were dose-related in both groups. At each dose, the A peaks in OB (VLD: 0.55+/-0.03 pmol/l, HD: 0.79+/-0.09 pmol/l; LD: 0.63+/-0.04 pmol/l, HD: 0.78+/-0.09 pmol/l) were similar to those in NS (VLD: 0.8+/-0.10 pmol/l, HD: 0.86+/-0.09 pmol/l; LD: 0.8+/-0.10 pmol/l, HD: 0.95+/-0.12 pmol/l). The peak DHEA responses to ACTH were dose-related in both groups. At each dose the DHEA peaks in OB (VLD: 58.6+/-13.3 nmol/l, HD: 61.9+/-13.1 nmol/l; LD: 55.18+/-6.4 nmol/l, HD: 72.3+/-9.8 nmol/l) were similar to those in NS (VLD: 54.3+/-8.2 nmol/l, HD: 57.8+/-8.2 nmol/l; LD: 42.2+/-3.7 nmol/l, HD: 56.9+/-4.3 nmol/l). CONCLUSIONS: This study shows that the cortisol, aldosterone and dehydroepiondrosterone responses to high, low and very low ACTH doses in obese women overlap with those in age-matched lean controls; these findings suggest normal sensitivity of the different zones of the adrenal cortex to ACTH in obesity.

Adolescent↗

Dissociation of plasma and urinary steroid values after application of stressors, insulin, vasopressin, ACTH, or dexamethasone in the Mongolian gerbil.

The amounts of cortisol and testosterone in the plasma or urine of Mongolian gerbils exposed to stress factors or treated subcutaneously with insulin (2 IU), vasopressin (1 IU), ACTH (6 IU) or dexamethasone (50 micrograms) were determined. Increased plasma cortisol was observed in animals stressed by ether anesthesia or immobilisation (1-4 hours), or treated with insulin, vasopressin or ACTH. Cortisol levels were reduced after dexamethasone administration. Plasma testosterone was elevated in animals stressed by ether anesthesia or handling plus seizure; no other treatment altered testosterone levels. An augmented cortisol excretion, which lasted one day, occurred in gerbils immobilised for one as well as for four hours. A much more prolonged stimulation of cortisol excretion, lasting three days, was seen in animals receiving ACTH or dexamethasone plus ACTH. Testosterone excretion was stimulated by ACTH and dexamethasone plus ACTH; it was not influenced by any other treatment. The present study shows that analysis of circulating steroid levels is the only reliable approach to assess the secretory activity of Mongolian gerbil adrenals or testes. In some experimental conditions (e.g. after stressor application or ACTH treatment) cortisol excretion may be used as an index of adrenal secretory function. In contrast, the striking differences between cortisol values present in plasma and urine of peptide-or dexamethasone-treated gerbils indicate that urinary cortisol does not reflect short-term changes of adrenal function. Similarly, the striking differences of testosterone values in plasma and urine indicate that urinary testosterone monitoring cannot be used to determine the secretory activity of gerbil testes.

Adrenocorticotropic Hormone↗

Effect of dexamethasone on steroidogenesis and on adrenocortical cyclic AMP and cyclic GMP responses to ACTH.

The inhibitory action of dexamethasone on the adrenal steroidogenic response to ACTH was confirmed by im administration of graded doses (5, 10 and 30 ng) of synthetic beta 1-24 ACTH to young adult male rats which had received dexamethasone (0.1 mg/100 g bw) 4 hr prior to sacrifice. Following this, kinetic studies were performed by measuring plasma corticosterone, adrenocortical cyclic AMP and cyclic GMP before and 4, 12 and 30 min after administration of either 10 or 30 ng of ACTH. These doses were selected because their effects could be either completely or partially inhibited by dexamethasone. In rats without dexamethasone all the doses of ACTH which were checked induced an increase in both corticosterone and cyclic AMP and a decrease in cyclic GMP. With the smallest dose of ACTH the earlier administration of dexamethasone resulted in complete suppression of both the steroidogenic response and the cyclic AMP response. With the largest dose of ACTH both responses were diminished. In dexamethasone-treated rats the decrease in cyclic GMP was significantly less pronounced 4 min after ACTH than it was in non-treated rats. These results support the view that cyclic AMP and cyclic GMP might both be concerned with the mechanism of acute adrenal steroidogenesis.

Adrenal Cortex↗

Endurance training in females: changes in beta-endorphin and ACTH.

Previous results from endurance training in women have been discrepant in regard to influences on basal and maximum adrenocorticotropin (ACTH) and beta-endorphin (beta-EP) concentrations before and after exhaustive exercise. A group of 23 untrained young women ran 3 times a week for 30 min at an individual specific intensity corresponding to their respective anaerobic threshold, derived from the lactate performance curve obtained from prior treadmill testing. ACTH and beta-EP were measured at rest, as well as 5 and 30 min after exhaustive progressive spiroergometric treadmill running, both before and after the 8 week endurance training program. Basal beta-EP did not change after training, but less elevated concentrations were measured both 5 (p < 0.05) and 30 min (p < 0.05) after exercise, after the training program. In contrast, the resting concentration of ACTH increased significantly; the respective maximum concentration was less elevated after 5 min and much less elevated 30 min after the exercise (p < 0.05). Positive correlations were found after the exhaustive exercise between beta-EP and ACTH, as well as between maximum lactate and ACTH. Training was associated with significant changes in maximum running speed (p < 0.01), maximum oxygen uptake (p < 0.01) and the running speed at the anaerobic threshold (p < 0.05). Maximum lactate and the level of perceived exertion remained unchanged, showing a similar level of exhaustion. Our results indicate that endurance training modulates the hormonal responses of beta-EP and ACTH to comparable workloads of high intensity. After the training program the maximum concentrations are significantly lower during the recovery period. The tendency to elevated basal ACTH, and thus elevated cortisol, might be a new factor to consider in evaluation of endurance training induced hormonal disturbances in women.

Adrenocorticotropic Hormone↗

Interleukin-1 potentiates basal and AVP-stimulated ACTH secretion in vitro--the role of CRH pre-incubation.

The acute-phase cytokine interleukin-1 (IL-1) is known to activate the hypothalamic pituitary adrenal axis, primarily via corticotropin releasing hormone (CRH). The aim of this study was to determine whether IL-1beta could directly stimulate ACTH secretion from perifused equine anterior pituitary cells, and whether CRH pre-incubation affected corticotroph responsiveness. Isolated equine anterior pituitary cells were pre-incubated with media containing 10 nM CRH or vehicle for 20 hours before being loaded onto columns and perifused with 0.02 nM CRH and 100 nM cortisol. Columns were given a 5-minute pulse of arginine vasopressin (AVP, 10 nM), perifused for 4 hours with 0 (control) or 1 nM IL-1beta, then given a further 5-minute pulse of AVP (10nM). ACTH was measured in 5 minute fractions. In the setting of CRH pre-incubation, cells perifused with IL-1beta for 4 hours showed increased basal ACTH secretion compared to control (114 +/- 6 pM vs. 86 +/- 4 pM [means +/- S.E.M.], p < 0.001) and a significantly greater ACTH response to the final AVP pulse (240 +/- 32% vs. 96 +/- 30%, p = 0.009, expressed as % of ACTH response to the initial AVP pulse). The potentiation of AVP-stimulated ACTH release by IL-1 was not observed in cells pre-incubated with vehicle alone. In conclusion, IL-1 increases ACTH release in equine corticotroph cells pre-incubated with CRH and potentiates responsivity to AVP.

Adrenocorticotropic Hormone↗